Table C36Exenatide patients with a BMI of 27 kg/m2 (exenatide results in a 0.016 utility increase due to 3% weight loss, and nausea compared to 3% increased weight gain and no nausea in other treatments applied for first 3 yrs), compared to a BMI 33 kg/m2

Total QALYsTotal costs (£)Inc. QALYInc. cost (£)ICER
Human insulin8.0119,746
Pioglitazone7.9720,123−0.03377dominated
Glargine7.9621,611−0.051,865dominated
Biphasic analogue8.0123,2410.003,496dominated
Rosiglitazone7.8925,045−0.125,299dominated
Exenatide8.1828,9750.179,230£54,550

From: Appendix C, Health economic analysis of third-line therapy with insulins, glitazones or exenatide in Type 2 diabetes

Cover of Type 2 Diabetes
Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update).
NICE Clinical Guidelines, No. 66.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.